Comparison of the effective dose of alfentanil for percutaneous thermal ablation in subcapsular versus non-subcapsular hepatocellular carcinoma: a prospective dose-finding study utilizing the up-and-down sequential allocation method Authors: Siqun Xiao, Die Qiu, Wen Zhang, Shunv Cai Published: 2025 ABSTRACT BackgroundPatients undergoing ultrasound-guided percutaneous thermal ablation for hepatocellular carcinoma (HCC) generally experience varying degrees of pain, with significantly more intense sensations particularly during ablation of subcapsular liver lesions. Alfentanil is routinely used for analgesia in brief interventions such as outpatient procedures. This study aimed to compare the median effective dose (ED50) of alfentanil between patients undergoing percutaneous thermal ablation for subcapsular and non-subcapsular HCC.MethodsSixty patients were divided into two groups: Group L (HCC border ≤ 5 mm from the hepatic capsule) and Group H (HCC border > 5 mm from the hepatic capsule). The initial effect-site concentration of alfentanil was set at 50 ng/mL for the first patient in both groups. Subsequent doses were adjusted using an up-down sequential method, wherein the concentration was increased or decreased by 10 ng/mL based on the previous patient’s response. Effective analgesia was defined as an intraoperative numerical rating scale (NRS) score of < 3 points without involuntary body movement. The ED50 of alfentanil was calculated for both groups using probit regression analysis.ResultsThe ED50 of alfentanil, calculated using probit regression, was 51.7 ng/mL (95% CI, 42.1–61.3 ng/mL) in Group L and 37.4 ng/mL (95% CI, 31.2–42.8 ng/mL) in Group H (P < 0.05).ConclusionIn percutaneous thermal ablation, the required dose of alfentanil is significantly higher for subcapsular HCC ablation than for non-subcapsular HCC ablation.Trial registrationRegistered in the Chinese Clinical Trial Registry (ChiCTR2400093729) on December 11, 2024.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-025-03582-1. Introduction Liver cancer ranks as the sixth most common malignancy and the third leading cause of cancer-related death worldwide [1]. Percutaneous thermal ablation effectively treats hepatocellular carcinoma (HCC) by inducing localized heat-mediated protein denaturation in tumor cells [2]. Compared to hepatectomy, percutaneous thermal ablation minimizes trauma and shortens hospitalization time [3]. During thermal ablation of HCC, pain experienced primarily arises from skin puncture and thermal energy transfer [4]. Radiologists often require patient cooperation to accurately confirm lesion location and needle positioning. However, patients may experience severe pain during the procedure, particularly when ablating lesions adjacent to the hepatic capsule [5–7]. Therefore, selecting an appropriate anesthesia protocol is crucial for the successful performance of percutaneous thermal ablation. Monitored anesthesia care (MAC) is commonly employed as the anesthetic technique for percutaneous thermal ablation. In contrast to general anesthesia, MAC aims to provide sedation and analgesia while maintaining the patient’s spontaneous ventilation and ability to respond to verbal commands [8]. Consequently, a precise opioid dosing is crucial during MAC. Alfentanil, a rapid-onset opioid analgesic with a short duration of action and rapid metabolism, is frequently used to provide anesthetic analgesia during brief procedures [9]. Alfentanil monotherapy for conscious sedation is associated with a low incidence of respiratory depression [10]. However, the minimum effective dose of alfentanil for ablation procedure is unknown. This study aimed to compare the ED50 of alfentanil between subcapsular and non-subcapsular HCC ablation procedures. Methods Participants This study was conducted at Zhejiang Cancer Hospital between December 2024 and March 2025. It was registered on the Chinese Clinical Trial Registry (www.chiCTR.org.cn) under the identifier ChiCTR2400093729 on December 11, 2024. This manuscript adhered to the CONSORT guidelines. The study protocol was approved by the Ethics Committee of Zhejiang Cancer Hospital (Approval No. IRB-2024-1172). Written informed consent was obtained from all patients before their participation in the study. Sixty patients who met the inclusion criteria were included in the final analysis. Patients undergoing thermal ablation for HCC under MAC were screened for eligibility. Inclusion criteria were: (1) age between 18 and 69 years; (2) diagnosis of a single HCC lesion with a maximum diameter ≤ 5 cm; (3) classification as American Society of Anesthesiologists (ASA) physical status I–III. Exclusion criteria comprised: (1) severe bradycardia (heart rate < 50 beats/min), sick sinus syndrome, or second-degree or higher atrioventricular block without a pacemaker; (2) portal hypertension or severe hepatic impairment (Child-Pugh class C); (3) renal failure requiring replacement therapy; (4) HCC greater than 5 cm; (5) refusal to participate. Demographic information, including age, height, and weight, was collected. Study protocol All patients fasted for at least 6 h and refrained from drinking for 2 h prior to the procedure. Tumors were localized using ultrasound or computed tomography, and patients were subsequently stratified into two groups: Group L (HCC border ≤ 5 mm from the hepatic capsule) and Group H (HCC border > 5 mm from the hepatic capsule). Before entering the operating room, patients were instructed on how to use the numeric rating scale (NRS) for pain assessment. Each patient was provided with a visual NRS aid card and clear verbal explanations. Their comprehension was then verified by having them score hypothetical pain scenarios. Only patients who demonstrated a logical understanding of the pain intensity scale proceeded to the formal study. Upon entering the operating room, peripheral intravenous access was established in an upper limb for fluid administration, and oxygen was delivered via nasal cannula at a flow rate of 2 L/min. Standard noninvasive monitoring was implemented, including noninvasive blood pressure (NIBP), heart rate (HR), peripheral oxygen saturation (SpO2), respiratory rate (RR), and electrocardiography (ECG). Baseline values for NIBP and HR were defined as the average of two consecutive measurements taken in the supine position. Intravenous medications included a 15-minute infusion of dexmedetomidine (0.5 µg/kg), followed by postoperative analgesics (500 mg paracetamol and 50 mg flurbiprofen axetil), and antiemetics (5 mg dexamethasone and 8 mg ondansetron). Intraoperative analgesia was maintained with a continuous infusion of alfentanil (Yichang Renfu Pharmaceutical Co., Ltd., Yichang, China) using a target-controlled infusion (TCI) pump (Hudson mode, effect-site concentration) to achieve the desired analgesic effect. The procedure began 90 s after the target alfentanil concentration was reached. The operator independently selected either radiofrequency or microwave ablation for each case. Prior to the insertion of the electrode needle into the tumor, local anesthesia was administered at the puncture site with 5 mL of 2% lidocaine. The initial alfentanil effect-site concentration was determined to be 50 ng/mL based on preliminary pretests. The target concentration for each patient was determined by an anesthesiologist not involved in patient assessment and communicated to a second anesthesiologist, blinded to the study objectives, who managed the intraoperative anesthesia. Alfentanil dosing was adjusted according to the Dixon sequential method. Effective analgesia was defined as maintaining a NRS pain score below 3 and preventing any involuntary body movement during the ablation. Based on the outcome in the preceding patient, the alfentanil concentration for the subsequent patient was increased or decreased by 10 ng/mL. In cases of intraoperative respiratory depression, defined as a RR < 8 breaths/min or SpO2 < 90%, the alfentanil concentration was immediately reduced by 20 ng/mL. Supplemental analgesia with alfentanil was administered when a patient’s NRS score ≥ 3. If a patient’s NRS score was ≥ 3, the alfentanil concentration was increased by 10 ng/mL; for NRS scores ≥ 5, the increment was 20 ng/mL, until the score dropped below 3. Following the procedure, patients were transferred to the recovery room for postoperative monitoring. Severe bradycardia (HR < 50 beats/min) or a ≥ 20% decrease in NIBP from baseline values was managed with 0.5 mg atropine or 5 mg ephedrine, as clinically indicated. Respiratory depression was treated using jaw-thrust maneuvers to maintain airway patency, with supplemental respiratory support provided when necessary. The primary outcome was the median effective dose (ED₅₀) of alfentanil. Pain severity was assessed in all patients using the numerical rating scale. Sedation depth was evaluated using the Modified Observer’s Assessment of Alertness/Sedation scale (MOAA/S), defined as follows: 5 = the patient responds normally to name calls in a regular tone; 4 = unresponsive to name calls in a normal tone; 3 = responsive only to repeated or loud name calls; 2 = responsive only to gentle pricking or shaking; 1 = responsive only to painful trapezius squeeze; 0 = unresponsive to trapezius squeeze [11]. Both NRS and MOAA/S scores were recorded at one-minute intervals throughout the procedure. Additionally, we documented the NRS score during electrode needle skin puncture, along with each patient’s maximum NRS score and minimum MOAA/S score during ablation. At the conclusion of the procedure, both the patient and the operator independently assessed their satisfaction with the effectiveness of analgesia using a three-point scale (1 = poor, 2 = moderate, 3 = satisfied). Intraoperative and recovery-phase adverse events, including bradycardia, hypotension, involuntary body movements, nausea, vomiting, and respiratory depression, were systematically recorded. Postoperative follow-up assessments were conducted at 1, 2 and 6 h after the procedure, during which NRS pain scores were documented. Statistical analysis According to the termination rule of the up-and-down sequential method, a sample size of 30 patients per group was sufficient to estimate the ED₅₀ [11–13]. Therefore, a total of 60 patients were included in the study. Continuous variables were presented as mean ± standard deviation (SD) or median with interquartile range (IQR), while categorical variables are expressed as counts and percentages. Data normality was assessed using the Shapiro-Wilk test. For normally distributed data, comparisons were made using Student’s t-test; the Mann-Whitney U test was used for non-normally distributed data. Categorical variables were analyzed using the Chi-square test or Fisher’s exact test, as appropriate. The ED₅₀ and its 95% confidence interval (CI) for alfentanil during thermal ablation in HCC patients were calculated using the probit regression method. A two-sided P-value of < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 26.0 (SPSS Inc., Chicago, IL, USA). Results As shown in Fig. 1, a total of 68 patients with HCC were screened for eligibility between December 2024 and March 2025. Of these, 60 patients met the inclusion criteria and were enrolled in the final analysis. Demographic data were presented in Table 1. There were no statistically significant differences in baseline demographics or clinical characteristics between the two groups, except for the alfentanil dose, which differed significantly. Fig. 1Flow diagram of study Flow diagram of study Table 1Baseline Characteristics and Intraprocedural VariablesGroup L(n = 30)Group H(n = 30)P-valueGender (male/female)18(60.0)/ 12 (40.0)21(70.0)/ 9 (30.0)0.417Age (years)58.5 (53.8–64.3)59.5 (54–64)0.668Weight (kg)61.5 ± 11.467.3 ± 130.070Height (cm)165.4 ± 8.4167.2 ± 7.60.393BMI (kg/m2)22.3 ± 2.923.9 ± 3.40.056Diabetes6(20.0)5(16.7)0.739Hypertension12(40.0)12(40.0)1STOP-Bang2(1–3)2(2-3.25)0.232Tumor size (cm)1.9(1.3–2.6)1.6(1.1–2.2)0.217Tumor adjacent to Glisson’s system03 (10.0)0.237Operation (radiofrequency/microwave)4 (13.3) / 26 (86.7)6 (20.0) / 24 (80.0)0.488Maximum power output (W)50 (50-62.5)60 (50-72.5)0.522Sedation time (min)30.8 ± 4.531.1 ± 5.30.813Total ablation time (min)6.8(5.2–7.6)6.7(5.0-10.1)0.663Dexmedetomidine dose (µg)31.3 ± 6.233.8 ± 6.50.122Alfentanil dose (mg)1.2(1.0-1.5)1.0(0.9–1.2)0.026*Data are expressed as the mean ± SD, median (interquartile range), or number of patients (percentage) as appropriateSTOP-Bang, snore loudly; Daytime Tiredness; Observed apneas; High blood pressure; Body mass index greater than 35; Age more than 35 year; Neck circumference more than 40 cm; G, male sex*P < 0.05 Table 1Baseline Characteristics and Intraprocedural VariablesGroup L(n = 30)Group H(n = 30)P-valueGender (male/female)18(60.0)/ 12 (40.0)21(70.0)/ 9 (30.0)0.417Age (years)58.5 (53.8–64.3)59.5 (54–64)0.668Weight (kg)61.5 ± 11.467.3 ± 130.070Height (cm)165.4 ± 8.4167.2 ± 7.60.393BMI (kg/m2)22.3 ± 2.923.9 ± 3.40.056Diabetes6(20.0)5(16.7)0.739Hypertension12(40.0)12(40.0)1STOP-Bang2(1–3)2(2-3.25)0.232Tumor size (cm)1.9(1.3–2.6)1.6(1.1–2.2)0.217Tumor adjacent to Glisson’s system03 (10.0)0.237Operation (radiofrequency/microwave)4 (13.3) / 26 (86.7)6 (20.0) / 24 (80.0)0.488Maximum power output (W)50 (50-62.5)60 (50-72.5)0.522Sedation time (min)30.8 ± 4.531.1 ± 5.30.813Total ablation time (min)6.8(5.2–7.6)6.7(5.0-10.1)0.663Dexmedetomidine dose (µg)31.3 ± 6.233.8 ± 6.50.122Alfentanil dose (mg)1.2(1.0-1.5)1.0(0.9–1.2)0.026*Data are expressed as the mean ± SD, median (interquartile range), or number of patients (percentage) as appropriateSTOP-Bang, snore loudly; Daytime Tiredness; Observed apneas; High blood pressure; Body mass index greater than 35; Age more than 35 year; Neck circumference more than 40 cm; G, male sex*P < 0.05 Table 1 Data are expressed as the mean ± SD, median (interquartile range), or number of patients (percentage) as appropriate STOP-Bang, snore loudly; Daytime Tiredness; Observed apneas; High blood pressure; Body mass index greater than 35; Age more than 35 year; Neck circumference more than 40 cm; G, male sex *P < 0.05 The sequence of positive and negative responses to alfentanil during thermal ablation in patients with HCC is illustrated in Fig. 2. Dose–response curves for both groups are shown in Fig. 3. The ‘Goodness of fit test’ X2 values for the probit regression models were 1.364 (P = 0.714) and 1.174 (P = 0.556), respectively, indicating an adequate model fit. The ED₅₀ values (95% CI) of alfentanil for percutaneous thermal ablation were 51.7 ng/mL (95% CI, 42.1–61.3 ng/mL) for tumors with border ≤ 5 mm from the hepatic capsule and 37.4 ng/mL (95% CI, 31.2–42.8 ng/mL) for those with border > 5 mm. This difference was statistically significant (P < 0.05). Fig. 2Sequence diagram of alfentanil for percutaneous thermal ablation. Solid circles represent ineffective reactions; hollow circles represent effective reactions. Solid line represents the ED50 (dashed lines represent the 95% confidence interval, CI) of alfentanil for percutaneous thermal ablation Sequence diagram of alfentanil for percutaneous thermal ablation. Solid circles represent ineffective reactions; hollow circles represent effective reactions. Solid line represents the ED50 (dashed lines represent the 95% confidence interval, CI) of alfentanil for percutaneous thermal ablation Fig. 3Dose-response curves for alfentanil for percutaneous thermal ablation in the two groups derived from probit regression analysis (Group L, blue curve; Group H, red curve). Dashed lines indicate the position of the estimates of ED50 Dose-response curves for alfentanil for percutaneous thermal ablation in the two groups derived from probit regression analysis (Group L, blue curve; Group H, red curve). Dashed lines indicate the position of the estimates of ED50 Patient characteristics related to effective analgesia are summarized in Table 2. No significant differences were observed between the two groups in terms of NRS scores or MOAA/S scores (P > 0.05). Likewise, patient and operator satisfaction scores did not differ significantly between the groups (P > 0.05). Table 2Characteristics of analgesia level, sedation depth and satisfaction under effective analgesiaGroup L(n = 15)Group H(n = 16)P-valueNRS of pain At skin puncture1.27 ± 0.461.31 ± 0.70.667 Maximum at ablation1.6 ± 0.511.56 ± 0.510.839 1 h after ablation1.06 ± 0.81.12 ± 0.890.849 2 h after ablation0.93 ± 1.161.06 ± 1.180.761 6 h after ablation0.53 ± 0.830.44 ± 0.720.735MOAA/S score Minimum at ablation4.4 ± 0.514.31 ± 0.60.666Patient satisfaction 3 − 2–1 (n)13 − 2–012- 3- 11Operator satisfaction 3 − 2–1 (n)15 − 0–015 − 0–11Data are presented as a number or mean ± SD; NRS numerical rating scale; Satisfaction was evaluated with a 3-point scale score (1 = poor, 2 = moderate, 3 = satisfied) Table 2Characteristics of analgesia level, sedation depth and satisfaction under effective analgesiaGroup L(n = 15)Group H(n = 16)P-valueNRS of pain At skin puncture1.27 ± 0.461.31 ± 0.70.667 Maximum at ablation1.6 ± 0.511.56 ± 0.510.839 1 h after ablation1.06 ± 0.81.12 ± 0.890.849 2 h after ablation0.93 ± 1.161.06 ± 1.180.761 6 h after ablation0.53 ± 0.830.44 ± 0.720.735MOAA/S score Minimum at ablation4.4 ± 0.514.31 ± 0.60.666Patient satisfaction 3 − 2–1 (n)13 − 2–012- 3- 11Operator satisfaction 3 − 2–1 (n)15 − 0–015 − 0–11Data are presented as a number or mean ± SD; NRS numerical rating scale; Satisfaction was evaluated with a 3-point scale score (1 = poor, 2 = moderate, 3 = satisfied) Table 2 Data are presented as a number or mean ± SD; NRS numerical rating scale; Satisfaction was evaluated with a 3-point scale score (1 = poor, 2 = moderate, 3 = satisfied) The incidence of adverse events in the two groups was presented in Table 3. There were no statistically significant differences between the groups in the occurrence of hypotension, bradycardia, nausea and vomiting, involuntary body movements, or respiratory depression (P > 0.05). Table 3Adverse eventsGroup L(n = 30)Group H(n = 30)P-valuehypotension (n)011bradycardia (n)230.640Nausea and vomiting (n)130.301Unwanted body movement (n)210.554Respiratory depression (n)001 Table 3Adverse eventsGroup L(n = 30)Group H(n = 30)P-valuehypotension (n)011bradycardia (n)230.640Nausea and vomiting (n)130.301Unwanted body movement (n)210.554Respiratory depression (n)001 Table 3 Discussion In this study, we evaluated the dose–response characteristics of alfentanil during percutaneous thermal ablation for HCC in patients with tumor border either ≤ 5 mm or > 5 mm from the hepatic capsule, and calculated the ED₅₀ values for both groups. The results demonstrated that patients with HCC located ≤ 5 mm from the hepatic capsule required significantly higher alfentanil doses during the procedure compared to those with tumor border > 5 mm. Treatment options for HCC include surgical resection, liver transplantation and ablation. Among these, ablation serves as a minimally invasive alternative to hepatic resection and transplantation, offering benefits of reduced trauma, fewer complications and shorter hospital stays [14]. Ultrasound-guided percutaneous thermal ablation effectively treats HCC by inducing localized coagulative necrosis in solid tumors at temperatures ranging from 60 °C to 100 °C. To achieve complete tumor eradication, the ablation zone is typically extended at least 5 mm beyond the visible tumor border, forming a critical safety buffer [2, 15]. However, this approach poses a risk of collateral thermal injury when treating subcapsular HCC, as it may affect the peritoneum and adjacent organs. Consequently, ablating lesions near the liver capsule tends to cause more severe pain compared to lesions located deeper within the hepatic parenchyma [16]. This study found that the ablation of subcapsular lesions was associated with a greater requirement for alfentanil. Interestingly, in a study employing paravertebral nerve blockade for radiofrequency ablation of HCC, an additional 3 ml of 2% lidocaine was administered to block the right phrenic nerve specifically for subcapsular lesions to improve procedural tolerance [17]. Ultrasound-guided thermal ablation for liver cancer is typically performed under MAC. Conscious sedation preserves patient responsiveness, enabling controlled respiratory maneuvers that reduce diaphragmatic excursion and enhance ultrasound visualization, thereby improving procedural accuracy [18]. However, patients under MAC often exhibit pain responses and involuntary movements during the delivery of radiofrequency energy [5]. Optimal conditions require the patient to maintain stable spontaneous respiration and remain motionless throughout the procedure [19]. In this study, patients maintained spontaneous respiration and were able to respond to the operator’s commands, resulting in a high level of operator satisfaction. Previous studies on thermal ablation for HCC under MAC have reported varying degrees of respiratory depression [5, 20]. During percutaneous thermal ablation of HCC, anesthesiologists must balance adequate sedation and analgesia with the maintenance of stable spontaneous respiration. Alfentanil, a rapid-acting µ-opioid receptor agonist administered intravenously, has an onset of action within 30 s and reaches peak effect in approximately 1.4 min, enabling precise titration to individual analgesic requirements [9, 21]. Compared to fentanyl and sufentail, alfentanil has a more rapid onset and shorter half-life, making it particularly well suited for brief procedures. Additionally, in comparison with the ultrashort-acting opioid remifentanil, alfentanil is associated with fewer respiratory and cardiovascular side effects [22]. Clinical trials have shown that alfentanil causes less postoperative nausea and vomiting than remifentanil, fentanyl and sufentanil [23, 24]. Although opioid-induced respiratory depression remains a potential concern, no cases of significant respiratory depression or excessive sedation were observed in this study. These findings are consistent with prior research indicating that alfentanil concentrations below 100 ng/mL are generally not associated with respiratory depression [25]. In this study, successful analgesia was characterized by minimal patient discomfort and high satisfaction rates among both patients and operators. This finding suggests that alfentanil represents a viable analgesic option for percutaneous thermal ablation. This study has several limitations. First, it was conducted at a single center with a small sample size, which may limit the generalizability of the findings. Second, we did not investigate the ED₉₅ of alfentanil for thermal ablation of hepatic tumors. Although the ED₅₀ provides useful information, the ED₉₅ is considered more clinically relevant for ensuring effective analgesia in a broader patient population and warrants further investigation. Third, the duration of the ablation procedure was approximately 7 min; therefore, it remains unclear whether prolonged infusion of alfentanil would increase the risk of respiratory or circulatory depression during longer procedures. Fourthly, this study has a methodological consideration regarding the estimation of alfentanil’s ED₅₀. All patients received dexmedetomidine, which possesses known analgesic properties. This co-administration may have reduced the overall opioid requirement, meaning that our ED₅₀ estimate likely reflects the clinically relevant dose of alfentanil when used as part of a multimodal regimen with dexmedetomidine, rather than its pure pharmacodynamic ED₅₀ in isolation. This design was intentional to simulate standard clinical practice. The balanced administration between groups ensures that the observed difference in ED₅₀ between them is robust. Finally, the depth of sedation was assessed clinically using the MOAA/S scale without confirmation by objective monitors such as the bispectral index (BIS). Although this represents standard clinical practice, relying solely on clinical sedation scales may introduce variability in assessing anesthetic depth. Future studies should aim to evaluate the ED₅₀ and ED₉₅ of alfentanil across varying procedure durations and patient populations. Conclusion In ultrasound-guided percutaneous thermal ablation procedures, the required dose of alfentanil is significantly higher for subcapsular HCC ablation than for non-subcapsular HCC ablation. Supplementary Information Supplementary Material 1. Supplementary Material 1.